EMEA-003081-PIP01-21
Table of contents
Key facts
| Active substance |
(1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2- trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
|
| Therapeutic area |
Infectious diseases
|
| Decision number |
P/0566/2021
|
| PIP number |
EMEA-003081-PIP01-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pfizer Europe MA EEIG
Tel. +44 (0)1304 646 607 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|